Physician profile
Amber Morrison
NPI 1992378830
$8,262.69
in general payments reported to CMS, 2019-2025
30 companies · $1,361 in 2025
The $1,361 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24.96 · 2022: $2,116 · 2023: $2,430 · 2024: $2,330 · 2025: $1,361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,106 · Education: $15.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,106.07 |
| Education | $15.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,972.38 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,007.89 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $998.56 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $726.98 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $609.63 | 2021-2025 | |
| Glaxosmithkline, LLC. | $422.38 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $308.05 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $306.39 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $258.24 | 2022-2025 | Rexulti |
| Corium, LLC | $247.26 | 2023-2025 | Azstarys |
| Merck Sharp & Dohme LLC | $192.00 | 2022-2025 | Gardasil 9, Vaxelis, M-M-R II |
| Amgen INC. | $176.56 | 2022-2025 | Repatha, Otezla, Repatha |
| Lundbeck LLC | $158.07 | 2023-2025 | Vyepti, Rexulti |
| Alkermes, INC. | $110.72 | 2024-2025 | Aristada, Lybalvi |
| Abbott Laboratories | $102.57 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $94.21 | 2022-2024 | Xifaxan, Trulance |
| Edwards Lifesciences Corporation | $91.83 | 2022 | |
| Axsome Therapeutics, INC. | $83.15 | 2023-2025 | Sunosi, Auvelity |
| Currax Pharmaceuticals LLC | $71.77 | 2022-2025 | Contrave |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $58.76 | 2022-2025 | Caplyta |
| Exact Sciences Corporation | $54.24 | 2024-2025 | Cologuard Collection Kit |
| Cranial Technologies, INC | $35.78 | 2023-2025 | Doc Band |
| Tolmar, INC. | $31.02 | 2023 | |
| Baxter Healthcare | $25.71 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Takeda Pharmaceuticals U.S.A., INC. | $22.75 | 2023 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.43 | 2022 | |
| Xeris Pharmaceuticals, INC. | $20.26 | 2023 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $20.05 | 2025 | Voquezna |
| Ultragenyx Pharmaceutical INC. | $18.09 | 2024 | Crysvita |
| Noven Therapeutics, LLC | $14.96 | 2023 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Morrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.